Patent Grant
7102059
The present invention relates to isolated DNA molecules corresponding to the open reading frames in the conserved effector loci and exchangeable effector loci of the Pseudomonas syringae, the isolated proteins encoded thereby, and their various uses.
The plant pathogenic bacterium Pseudomonas syringae is noted for its diverse and host-specific interactions with plants (Hirano and Upper, 1990). A specific strain may be assigned to one of at least 40 pathovars based on its host range among different plant species and then further assigned to a race based on differential interactions among cultivars of the host. In host plants the bacteria typically grow to high population levels in leaf intercellular spaces and then produce necrotic lesions. In nonhost plants or in host plants with race-specific resistance, the bacteria elicit the hypersensitive response (HR), a rapid, defense-associated programmed death of plant cells in contact with the pathogen (Alfano and Collmer, 1997). The ability to produce either of these reactions in plants appears to be directed by hrp (HR and pathogenicity) and hrc (HR and conserved) genes that encode a type III protein secretion pathway and by avr (avirulence) and hop (Hrp-dependent outer protein) genes that encode effector proteins injected into plant cells by the pathway (Alfano and Collmer, 1997). These effectors may also betray the parasite to the HR-triggering R-gene surveillance system of potential hosts (hence the avr designation), and plant breeding for resistance based on such gene-for-gene (avr-R) interactions may produce complex combinations of races and differential cultivars (Keen, 1990). hrp/hrc genes are probably universal among necrosis-causing gram-negative plant pathogens, and they have been sequenced in P. syringae pv. syringae (Psy) 61, Erwinia amylovora Ea321, Xanthomonas campestris pv. vesicatoria (Xcv) 85-10, and Ralstonia solanacearum GMI1000 (Alfano and Collmer, 1997). Based on their distinct gene arrangements and regulatory components, the hrp/hrc gene clusters of these four bacteria can be divided into two groups: I (Pseudomonas and Erwinia) and II (Xanthomonas and Ralstonia). The discrepancy between the distribution of these groups and the phylogeny of the bacteria provides some evidence that hrp/hrc gene clusters have been horizontally acquired and, therefore, may represent pathogenicity islands (Pais) (Alfano and Collmer, 1997).
Pais have been defined as gene clusters that (i) include many virulence genes, (ii) are selectively present in pathogenic strains, (iii) have different G+C content compared to host bacteria DNA, (iv) occupy large chromosomal regions, (v) are often flanked by direct repeats, (vi) are bordered by tRNA genes and/or cryptic mobile genetic elements, and (vii) are unstable (Hacker et al., 1997). Some Pais have inserted into different genomic locations in the same species (Wieler et al., 1997). Others reveal a mosaic structure indicative of multiple horizontal acquisitions (Hensel et al., 1999). Genes encoding type III secretion systems are present in Pais in animal pathogenic Salmonella spp. and Pseudomonas aeruginosa and on large plasmids in Yersinia and Shigella spp. Genes encoding effectors secreted by the pathway in these organisms are commonly linked to the pathway genes (Hueck, 1998), although a noteworthy exception is sopE, which is carried by a temperate phage without apparent linkage to SPI1 in certain isolates of S. typhimurium (Mirold et al., 1999). Three avr/hop genes have already been shown to be linked to the hrp/hrc cluster in P. syringae: avrE and several other Hrp-regulated transcriptional units are linked to the hrpR border of the hrp cluster in P. syringae pv tomato (Pto) DC3000 (Lorang and Keen, 1995); avrPphE is adjacent to hrpY (hrpK) in Pseudomonas phaseolicola (Pph) 1302A (Mansfield et al., 1994); and hopPsyA (hrmA) is adjacent to hrpK in Psy 61 (Heu and Hutcheson, 1993). Other Pseudomonas avr genes are located elsewhere in the genome or on plasmids (Leach and White, 1996), including a plasmid-borne group of avr genes described as a Pai in Pph 1449B (Jackson et al., 1999).
Because Avr, Hop, Hrp, and Hrc proteins represent promising therapeutic treatments in both plants and animals, it would be desirable to identify other proteins encoded by the Pai's in pathogenic bacteria and identify uses for those proteins.
The present invention overcomes these deficiencies in the art.
One aspect of the present invention relates to isolated nucleic acid molecules (i) encoding proteins or polypeptides of Pseudomonas Conserved Effector Loci (“CEL”) and Exchangeable Effector Loci (“EEL”) genomic regions, (ii) nucleic acid molecules which hybridize thereto under stringent conditions, or (iii) nucleic acid molecules that include a nucleotide sequence which is complementary to the nucleic acid molecules of (i) and (ii). Expression vectors, host cells, and transgenic plants which include the DNA molecules of the present invention are also disclosed. Methods of making such host cells and transgenic plant are disclosed.
A further aspect of the present invention relates to isolated proteins or polypeptides encoded by the nucleic acid molecules of the present invention. Compositions which contain the proteins are also disclosed.
Yet another aspect of the present invention relates to methods of imparting disease resistance to a plant. According to one approach, this method is carried out by transforming a plant cell with a heterologous DNA molecule of the present invention and regenerating a transgenic plant from the transformed plant cell, wherein the transgenic plant expresses the heterologous DNA molecule under conditions effective to impart disease resistance. According to another approach, this method is carried out by treating a plant with a protein or polypeptide of the present invention under conditions effective to impart disease resistance to the treated plant.
A still further aspect of the present invention relates to a method of making a plant hypersusceptible to colonization by nonpathogenic bacteria. According to one approach, this method is carried out by transforming a plant cell with a heterologous DNA molecule of the present invention and regenerating a transgenic plant from the transformed plant cell, wherein the transgenic plant expresses the heterologous DNA molecule under conditions effective to render the transgenic plant hypersusceptible to colonization by nonpathogenic bacteria. According to an alternative approach, this method is carried out by treating a plant with a protein or polypeptide of the present invention under conditions effective to render the treated plant susceptible to colonization by nonpathogenic bacteria.
Another aspect of the present invention relates to a method of causing eukaryotic cell death by introducing into a eukaryotic cell a cytotoxic Pseudomonas protein, where the introducing is performed under conditions effective to cause cell death.
A further aspect of the present invention relates to a method of treating a cancerous condition by introducing a cytotoxic Pseudomonas protein into cancer cells of a patient under conditions effective to cause death of cancer cells, thereby treating the cancerous condition.
The benefits of the present invention result from three factors. First, there is substantial and growing evidence that phytopathogen effector proteins have evolved to elicit exquisite changes in eukaryote metabolism at extremely low levels, and at least some of these activities are potentially relevant to mammals and other organisms in addition to plants. For example, ORF5 in the Psy B728a EEL is similar to Xanthomonas campestris pv. vesicatoria AvrBsT, a phytopathogen protein that appears to have the same active site as its animal pathogen homolog YopJ, which inhibits mammalian MAPKK defense signaling (Orth et al., 2000). Second, the P. syringae CEL and EEL regions are enriched in effector protein genes, which makes these regions fertile targets for effector gene bioprospecting. Third, rapidly developing technologies for delivering genes and proteins into plant and animal cells improve the efficacy of protein-based therapies.
A DNA molecule which contains the CEL of Pseudomonas syringae pv. tomato DC3000 has a nucleotide sequence (SEQ. ID. No. 1) as follows:
Several undefined nucleotides exist in SEQ. ID. No. 1, however these appear to be present in intergenic regions. The CEL of Pseudomonas syringae pv. tomato DC3000 contains a number of open reading frames (ORFs). Two of the products encoded by the CEL are HrpW and AvrE, both of which are known. An additional 10 products are produced by ORF1-10, respectively, as shown in
The DNA molecule of ORF3 from the Pseudomonas syringae pv. tomato DC3000 CEL has a nucleotide sequence (SEQ. ID. No. 2) as follows:
The protein or polypeptide encoded by Pto DC3000 CEL ORF3 has an amino acid sequence (SEQ. ID. No. 3) as follows:
The DNA molecule of ORF4 from the Pseudomonas syringae pv. tomato DC3000 CEL has a nucleotide sequence (SEQ. ID. No. 4) as follows:
The protein or polypeptide encoded by Pto DC3000 CEL ORF4 has an amino acid sequence (SEQ. ID. No. 5) as follows:
The DNA molecule of ORF5 from the Pseudomonas syringae pv. tomato DC3000 CEL has a nucleotide sequence (SEQ. ID. No. 6) as follows:
The protein or polypeptide encoded by Pto DC3000 CEL ORF5, now known as HopPtoA, has an amino acid sequence (SEQ. ID. No. 7) as follows:
The DNA molecule of ORF6 from the Pseudomonas syringae pv. tomato DC3000 CEL has a nucleotide sequence (SEQ. ID. No. 8) as follows:
The protein or polypeptide encoded by Pto DC3000 CEL ORF6 has an amino acid sequence (SEQ. ID. No. 9) as follows:
The DNA molecule of ORF7 from the Pseudomonas syringae pv. tomato DC3000 CEL has a nucleotide sequence (SEQ. ID. No. 10) as follows:
The protein or polypeptide encoded by Pto DC3000 CEL ORF7 has an amino acid sequence (SEQ. ID. No. 11) as follows:
The DNA molecule of ORF8 from the Pseudomonas syringae pv. tomato DC3000 CEL has a nucleotide sequence (SEQ. ID. No. 12) as follows:
The protein or polypeptide encoded by Pto DC3000 CEL ORF8 has an amino acid sequence (SEQ. ID. No. 13) as follows:
The DNA molecule of ORF9 from the Pseudomonas syringae pv. tomato DC3000 CEL has a nucleotide sequence (SEQ. ID. No. 14) as follows:
The protein or polypeptide encoded by Pto DC3000 CEL ORF9 has an amino acid sequence (SEQ. ID. No. 15) as follows:
The DNA molecule of ORF1O from the Pseudomonas syringae pv. tomato DC3000 CEL has a nucleotide sequence (SEQ. ID. No. 16) as follows:
The protein or polypeptide encoded by Pto DC3000 CEL ORF10 has an amino acid sequence (SEQ. ID. No. 17) as follows:
A DNA molecule which contains the EEL of Pseudomonas syringae pv. tomato DC3000 has a nucleotide sequence (SEQ. ID. No. 18) as follows:
Several undefined nucleotides exist in SEQ. ID. No. 18, however these appear to be present in intergenic regions. The EEL of Pseudomonas syringae pv. tomato DC3000 contains a number of ORFs. One of the products encoded by the EEL is a homolog of TnpA′ from P. stutzeri. An additional four products are produced by ORF1–4, respectively. The nucleotide sequences for a number of these ORFs and their encoded protein or polypeptide products are provided below.
The DNA molecule of ORF1 from the Pseudomonas syringae pv. tomato DC3000 EEL has a nucleotide sequence (SEQ. ID. No. 19) as follows:
The protein or polypeptide encoded by Pto DC3000 EEL ORF1 has an amino acid sequence (SEQ. ID. No. 20) as follows:
The DNA molecule of ORF2 from the Pseudomonas syringae pv. tomato DC3000 EEL has a nucleotide sequence (SEQ. ID. No. 21) as follows:
The protein or polypeptide encoded by Pto DC3000 EEL ORF2 has an amino acid sequence (SEQ. ID. No. 22) as follows:
The DNA molecule of ORF3 from the Pseudomonas syringae pv. tomato DC3000 EEL has a nucleotide sequence (SEQ. ID. No. 23) as follows:
The protein or polypeptide encoded by Pto DC3000 EEL ORF3 has an amino acid sequence (SEQ. ID. No. 24) as follows:
P. s. syringae pv. tomato DC3000 EEL ORF3 has now been shown to significantly reduce virulence when mutated. Perhaps more interestingly, overexpression strongly increases lesion size. Hence, this effector is biologically active and appears to have a key role in symptom production.
The DNA molecule of ORF4 from the Pseudomonas syringae pv. tomato DC3000 EEL has a nucleotide sequence (SEQ. ID. No. 25) as follows:
The protein or polypeptide encoded by Pto DC3000 EEL ORF4 has an amino acid sequence (SEQ. ID. No. 26) as follows:
The EEL of Pseudomonas syringae pv. syringae B728a contains a number of ORFs. Two of the open reading frames appear to be mobile genetic elements without comparable homologs in EELs of other Pseudomonas syringae variants. An additional four products are produced by ORF1-2 and ORF5-6, respectively. The nucleotide sequences for a number of these ORFs and their encoded protein or polypeptide products are provided below.
The DNA molecule of ORF1 from the Pseudomonas syringae pv. syringae B728a EEL has a nucleotide sequence (SEQ. ID. No. 27) as follows:
The protein or polypeptide encoded by Psy B728a EEL ORF1 has an amino acid sequence (SEQ. ID. No. 28) as follows:
As indicated in Table 1 (see Example 2), the DNA molecule encoding this protein or polypeptide bears significant homology to the nucleotide sequence from Pseudomonas syringae pv. phaseolicola which encodes AvrPphC.
The DNA molecule of ORF2 from the Pseudomonas syringae pv. syringae B728a EEL has a nucleotide sequence (SEQ. ID. No. 29) as follows:
The protein or polypeptide encoded by Psy B728a EEL ORF2 has an amino acid sequence (SEQ. ID. No. 30) as follows:
As indicated in Table 1 (see Example 2), the DNA molecule encoding this protein or polypeptide bears significant homology to the nucleotide sequence from Pseudomonas syringae pv. phaseolicola which encodes AvrPphE.
The DNA molecule of ORF5 from the Pseudomonas syringae pv. syringae B728a EEL has a nucleotide sequence (SEQ. ID. No. 31) as follows:
The protein or polypeptide encoded by Psy B728a EEL ORF5 has an amino acid sequence (SEQ. ID. No. 32) as follows:
The DNA molecule of ORF6 from the Pseudomonas syringae pv. syringae B728a EEL has a nucleotide sequence (SEQ. ID. No. 33) as follows:
The protein or polypeptide encoded by Psy B728a EEL ORF6 has an amino acid sequence (SEQ. ID. No. 34) as follows:
The EEL of Pseudomonas syringae pv. syringae 61 contains a number of ORFs. One of the open reading frames encodes the outer membrane protein HopPsyA. The DNA molecule which encodes HopPsyA has a nucleotide sequence (SEQ. ID. No. 35) as follows:
HopPsyA has an amino acid sequence (SEQ. ID. No. 36) as follows:
The remaining open reading frame, designated shcA, is a DNA molecule having a nucleotide sequence (SEQ. ID. No. 37) as follows:
The encoded protein or polypeptide, ShcA, has an amino acid sequence (SEQ. ID. No. 38) as follows:
In addition to the above DNA molecules and proteins or polypeptides, the present invention also relates to homologs of various DNA molecules of the present invention which have been isolated from other Pseudomonas syringae pathovars. For example, a number of AvrPphE, AvrPphF, and HopPsyA homologs have been identified from Pseudomonas syringae pathovars.
The DNA molecule from Pseudomonas syringae pv. angulata which encodes an AvrPphE homolog has a nucleotide sequence (SEQ. ID. No. 39) as follows:
The amino acid sequence (SEQ. ID. No. 40) for the AvrPphE homolog of Pseudomonas syringae pv. angulata is as follows:
This protein or polypeptide has GC content of about 57 percent, an estimated isoelectric point of about 9.5, and an estimated molecular weight of about 41 kDa.
The DNA molecule from Pseudomonas syringae pv. glycinea which encodes an AvrPphE homolog has a nucleotide sequence (SEQ. ID. No. 41) as follows:
The amino acid sequence (SEQ. ID. No. 42) for the AvrPphE homolog of Pseudomonas syringae pv. glycinea is as follows:
This protein or polypeptide has GC content of about 57 percent, an estimated isoelectric point of about 9.1, and an estimated molecular weight of about 41 kDa.
The DNA molecule from Pseudomonas syringae pv. tabaci which encodes an AvrPphE homolog has a nucleotide sequence (SEQ. ID. No. 43) as follows:
The amino acid sequence (SEQ. ID. No. 44) for the AvrPphE homolog of Pseudomonas syringae pv. tabaci is as follows:
This protein or polypeptide has GC content of about 57 percent, an estimated isoelectric point of about 9.3, and an estimated molecular weight of about 41 kDa.
Another DNA molecule from Pseudomonas syringae pv. tabaci which encodes a AvrPphE homolog has a nucleotide sequence (SEQ. ID. No. 45) as follows:
The encoded AvrPphE homolog has an amino acid sequence according to SEQ. ID. No. 46 as follows:
A DNA molecule from Pseudomonas syringae pv. glycinea race 4 which encodes an AvrPphE homolog has a nucleotide sequence (SEQ. ID. No. 47) as follows:
The encoded AvrPphE homolog has an amino acid sequence according to SEQ. ID. No. 48 as follows:
A DNA molecule from Pseudomonas syringae pv. phaseolicola strain B1330 which encodes AvrPphE has a nucleotide sequence (SEQ. ID. No. 49) as follows:
The encoded AvrPphE homolog has an amino acid sequence according to SEQ. ID. No. 50 as follows:
A DNA molecule from Pseudomonas syringae pv. angulata strain Pa9 which encodes an AvrPphE homolog has a nucleotide sequence (SEQ. ID. No. 51) as follows:
The encoded AvrPphE homolog has an amino acid sequence according to SEQ. ID. No. 52 as follows:
A DNA molecule from Pseudomonas syringae pv. delphinii strain PDDCC529 which encodes a AvrPphE homolog has a nucleotide sequence (SEQ. ID. No. 53) as follows:
The encoded AvrPphE homolog has an amino acid sequence according to SEQ. ID. No. 54 as follows:
A DNA molecule from Pseudomonas syringae pv. delphinii strain PDDCC529 which encodes a homolog of P. syringae pv. tomato DC3000 EEL ORF2 has a nucleotide sequence (SEQ. ID. No. 55) as follows:
The encoded protein or polypeptide has an amino acid sequence according to SEQ. ID. No. 56 as follows:
A DNA molecule from Pseudomonas syringae pv. delphinii strain PDDCC529 ORF1 encodes a homolog of AvrPphF and has a nucleotide sequence (SEQ. ID. No. 57) as follows:
The encoded AvrPhpF homolog has an amino acid sequence according to SEQ. ID. No. 58 as follows:
A DNA molecule from Pseudomonas syringae pv. delphinii strain PDDCC529 ORF1 encodes a homolog of AvrPphF and has a nucleotide sequence (SEQ. ID. No. 59) as follows:
The encoded AvrPphF homolog has an amino acid sequence according to SEQ. ID. No. 60 as follows:
A DNA molecule from Pseudomonas syringae pv. syringae strain 226 encodes a homolog of HopPsyA and has a nucleotide sequence (SEQ. ID. No. 61) as follows:
The encoded HopPsyA homolog has an amino acid sequence according to SEQ. ID. No. 62 as follows:
A DNA molecule from Pseudomonas syringae pv. atrofaciens strain B143 encodes a homolog of HopPsyA and has a nucleotide sequence (SEQ. ID. No. 63) as follows:
The encoded HopPsyA homolog has an amino acid sequence according to SEQ. ID. No. 64 as follows:
A DNA molecule from Pseudomonas syringae pv. tomato strain DC3000 encodes a homolog of HopPtoA, identified herein as HopPtoA2, and has a nucleotide sequence (SEQ. ID. No. 65) as follows:
Although hopPtoA2 does not lie within the CEL, it is included here as a homolog of hopPtoA, which corresponds to CEL ORF5 as noted above. The encoded HopPtoA2 protein or polypeptide has an amino acid sequence according to SEQ. ID. No. 66 as follows:
Fragments of the above-identified proteins or polypeptides as well as fragments of full length proteins from the EELs and CELs of other bacteria, in particular Gram-negative pathogens, can also be used according to the present invention.
Suitable fragments can be produced by several means. Subclones of the gene encoding a known protein can be produced using conventional molecular genetic manipulation for subcloning gene fragments, such as described by Sambrook et al., 1989, and Ausubel et al., 1994. The subclones then are expressed in vitro or in vivo in bacterial cells to yield a smaller protein or polypeptide that can be tested for activity, e.g., as a product required for pathogen virulence.
In another approach, based on knowledge of the primary structure of the protein, fragments of the protein-coding gene may be synthesized using the PCR technique together with specific sets of primers chosen to represent particular portions of the protein (Erlich et al., 1991). These can then be cloned into an appropriate vector for expression of a truncated protein or polypeptide from bacterial cells as described above.
As an alternative, fragments of a protein can be produced by digestion of a full-length protein with proteolytic enzymes like chymotrypsin or Staphylococcus proteinase A, or trypsin. Different proteolytic enzymes are likely to cleave different proteins at different sites based on the amino acid sequence of the particular protein. Some of the fragments that result from proteolysis may be active virulence proteins or polypeptides.
Chemical synthesis can also be used to make suitable fragments. Such a synthesis is carried out using known amino acid sequences for the polyppetide being produced. Alternatively, subjecting a full length protein to high temperatures and pressures will produce fragments. These fragments can then be separated by conventional procedures (e.g., chromatography, SDS-PAGE).
Variants may also (or alternatively) be modified by, for example, the deletion or addition of amino acids that have minimal influence on the properties, secondary structure and hydropathic nature of the polypeptide. For example, a polypeptide may be conjugated to a signal (or leader) sequence at the N-terminal end of the protein which co-translationally or post-translationally directs transfer of the protein. The polypeptide may also be conjugated to a linker or other sequence for ease of synthesis, purification, or identification of the polypeptide.
The proteins or polypeptides used in accordance with the present invention are preferably produced in purified form (preferably at least about 80%, more preferably 90%, pure) by conventional techniques. Typically, the protein or polypeptide of the present invention is secreted into the growth medium of recombinant host cells (discussed infra). Alternatively, the protein or polypeptide of the present invention is produced but not secreted into growth medium. In such cases, to isolate the protein, the host cell (e.g., E. coli) carrying a recombinant plasmid is propagated, lysed by sonication, heat, or chemical treatment, and the homogenate is centrifuged to remove bacterial debris. The supernatant is then subjected to sequential ammonium sulfate precipitation. The fraction containing the protein or polypeptide of interest is subjected to gel filtration in an appropriately sized dextran or polyacrylamide column to separate the proteins. If necessary, the protein fraction may be further purified by HPLC.
DNA molecules encoding other EEL and CEL protein or polypeptides can be identified using a PCR-based methodology for cloning portions of the pathogenicity islands of a bacterium. Basically, the PCR-based strategy involves the use of conserved sequences from the hrpK and tRNAleu genes (or other conserved border sequences) as primers for cloning EEL intervening regions of the pathogenicity island. As shown in
Using the above-described PCR-based methods, a number of DNA sequences were utilized as the source for primers. One such DNA molecule is isolated from the tRNAleu gene of Pseudomonas syringae pv. tomato DC3000, which has a nucleotide sequence (SEQ. ID. No. 67) as follows:
An additional DNA molecule which can be used to supply suitable primers is from the tRNAleu gene of Pseudomonas syringae pv. syringae B728a, which has a nucleotide sequence (SEQ. ID. No. 68) as follows:
Another DNA molecule is isolated from the queA gene of Pseudomonas syringae pv. tomato DC3000, which has a nucleotide sequence (SEQ. ID. No. 69) as follows:
This DNA molecule encodes QueA, which has an amino acid sequence (SEQ. ID. No. 70) as follows:
DNA molecules encoding other EEL and GEL proteins or polypeptides can also be identified by determining whether such DNA molecules hybridize under stringent conditions to a DNA molecule as identified above. An example of suitable stringency conditions is when hybridization is carried out at a temperature of about 37° C. using a hybridization medium that includes 0.9M sodium citrate (“SSC”) buffer, followed by washing with 0.2×SSC buffer at 37° C. Higher stringency can readily be attained by increasing the temperature for either hybridization or washing conditions or decreasing the sodium concentration of the hybridization or wash medium. Nonspecific binding may also be controlled using any one of a number of known techniques such as, for example, blocking the membrane with protein-containing solutions, addition of heterologous RNA, DNA, and SDS to the hybridization buffer, and treatment with RNase. Wash conditions are typically performed at or below stringency. Exemplary high stringency conditions include carrying out hybridization at a temperature of about 42° C. to about 65° C. for up to about 20 hours in a hybridization medium containing 1M NaCl, 50 mM Tris-HCl, pH 7.4, 10 mM EDTA, 0.1% sodium dodecyl sulfate (SDS), 0.2% ficoll, 0.2% polyvinylpyrrolidone, 0.2% bovine serum albumin, and 50 μg/ml E. coli DNA, followed by washing carried out at between about 42° C. to about 65° C. in a 0.2×SSC buffer.
Also encompassed by the present invention are nucleic acid molecules which contain conserved substitutions as compared to the above identified DNA molecules and, thus, encode the same protein or polypeptides identified above. Further, complementary sequences are also encompassed by the present invention.
The nucleic acid of the present invention can be either DNA or RNA, which can readily be prepared using the above identified DNA molecules of the present invention.
The delivery of effector proteins or polypeptides can be achieved in several ways, depending upon the host being treated and the materials being used: (1) as a stable or plasmid-encoded transgene; (2) transiently expressed via Agrobacterium or viral vectors; (3) delivered by the type III secretion systems of disarmed pathogens or recombinant nonpathogenic bacteria which express a functional, heterologous type III secretion system; or (4) delivered via topical application followed by TAT protein transduction domain-mediated spontaneous uptake into cells. Each of these is discussed infra.
The DNA molecule encoding the protein or polypeptide can be incorporated in cells using conventional recombinant DNA technology. Generally, this involves inserting the DNA molecule into an expression system to which the DNA molecule is heterologous (i.e. not normally present). The heterologous DNA molecule is inserted into the expression system or vector in proper sense orientation and correct reading frame. The vector contains the necessary elements for the transcription and translation of the inserted protein-coding sequences.
U.S. Pat. No. 4,237,224 to Cohen and Boyer describes the production of expression systems in the form of recombinant plasmids using restriction enzyme cleavage and ligation with DNA ligase. These recombinant plasmids are then introduced by means of transformation and replicated in unicellular cultures including prokaryotic organisms and eukaryotic cells grown in tissue culture.
Recombinant genes may also be introduced into viruses, such as vaccina virus. Recombinant viruses can be generated by transfection of plasmids into cells infected with virus.
Suitable vectors include, but are not limited to, the following viral vectors such as lambda vector system gt11, gt WES.tB, Charon 4, and plasmid vectors such as pBR322, pBR325, pACYC177, pACYC1084, pUC8, pUC9, pUC18, pUC19, pLG339, pR290, pKC37, pKC101, SV 40, pBluescript II SK +/− or KS +/− (see “Stratagene Cloning Systems” Catalog (1993) from Stratagene, La Jolla, Calif., which is hereby incorporated by reference), pQE, pIH821, pGEX, pET series (see Studier et al., 1990). Recombinant molecules can be introduced into cells via transformation, particularly transduction, conjugation, mobilization, or electroporation. The DNA sequences are cloned into the vector using standard cloning procedures in the art, as described by Sambrook et al., 1989.
A variety of host-vector systems may be utilized to express the protein-encoding sequence(s). Primarily, the vector system must be compatible with the host cell used. Host-vector systems include, but are not limited to, the following: bacteria transformed with bacteriophage DNA, plasmid DNA, or cosmid DNA; microorganisms such as yeast containing yeast vectors; mammalian cell systems infected with virus (e.g., vaccinia virus, adenovirus, etc.); insect cell systems infected with virus (e.g., baculovirus); and plant cells infected by bacteria. The expression elements of these vectors vary in their strength and specificities. Depending upon the host-vector system utilized, any one of a number of suitable transcription and translation elements can be used.
Different genetic signals and processing events control many levels of gene expression (e.g., DNA transcription and messenger RNA (mRNA) translation).
Transcription of DNA is dependent upon the presence of a promoter which is a DNA sequence that directs the binding of RNA polymerase and thereby promotes mRNA synthesis. The DNA sequences of eukaryotic promoters differ from those of prokaryotic promoters. Eukaryotic promoters and accompanying genetic signals may not be recognized in or may not function in a prokaryotic system and, further, prokaryotic promoters are not recognized and do not function in eukaryotic cells.
Similarly, translation of mRNA in prokaryotes depends upon the presence of the proper prokaryotic signals which differ from those of eukaryotes. Efficient translation of mRNA in prokaryotes requires a ribosome binding site called the Shine-Dalgarno (“SD”) sequence on the mRNA. This sequence is a short nucleotide sequence of mRNA that is located before the start codon, usually AUG, which encodes the amino-terminal methionine of the protein. The SD sequences are complementary to the 3′-end of the 16S rRNA (ribosomal RNA) and probably promote binding of mRNA to ribosomes by duplexing with the rRNA to allow correct positioning of the ribosome. For a review on maximizing gene expression, see Roberts and Lauer, 1979.
Promoters vary in their “strength” (i.e., their ability to promote transcription). For the purposes of expressing a cloned gene, it is desirable to use strong promoters in order to obtain a high level of transcription and, hence, expression of the gene. Depending upon the host cell system utilized, any one of a number of suitable promoters may be used. For instance, when cloning in E. coli, its bacteriophages, or plasmids, promoters such as the T7 phage promoter, lac promoter, trp promoter, recA promoter, ribosomal RNA promoter, the PR and PL promoters of coliphage lambda and others, including but not limited, to lacUV5, ompF, bla, lpp, and the like, may be used to direct high levels of transcription of adjacent DNA segments. Additionally, a hybrid trp-lacUV5 (tac) promoter or other E. coli promoters produced by recombinant DNA or other synthetic DNA techniques may be used to provide for transcription of the inserted gene.
Bacterial host cell strains and expression vectors may be chosen which inhibit the action of the promoter unless specifically induced. In certain operations, the addition of specific inducers is necessary for efficient transcription of the inserted DNA. For example, the lac operon is induced by the addition of lactose or IPTG (isopropylthio-beta-D-galactoside). A variety of other operons, such as trp, pro, etc., are under different controls.
Specific initiation signals are also required for efficient gene transcription and translation in prokaryotic cells. These transcription and translation initiation signals may vary in “strength” as measured by the quantity of gene specific messenger RNA and protein synthesized, respectively. The DNA expression vector, which contains a promoter, may also contain any combination of various “strong” transcription and/or translation initiation signals. For instance, efficient translation in E. coli requires an SD sequence about 7–9 bases 5′ to the initiation codon (“ATG”) to provide a ribosome binding site. Thus, any SD-ATG combination that can be utilized by host cell ribosomes may be employed. Such combinations include but are not limited to the SD-ATG combination from the cro gene or the N gene of coliphage lambda, or from the E. coli tryptophan E, D, C, B or A genes. Additionally, any SD-ATG combination produced by recombinant DNA or other techniques involving incorporation of synthetic nucleotides may be used.
Once the isolated DNA molecule encoding the polypeptide or protein has been cloned into an expression system, it is ready to be incorporated into a host cell. Such incorporation can be carried out by the various forms of transformation noted above, depending upon the vector/host cell system. Suitable host cells include, but are not limited to, bacteria, virus, yeast, mammalian cells, insect, plant, and the like.
Because it is desirable for recombinant host cells to secrete the encoded protein or polypeptide, it is preferable that the host cell also possess a functional type III secretion system. The type III secretion system can be heterologous to host cell (Ham et al., 1998) or the host cell can naturally possess a type III secretion system. Host cells which naturally contain a type III secretion system include many pathogenic Gram-negative bacterium, such as numerous Erwinia species, Pseudomonas species, Xanthomonas species, etc. Other type III secretion systems are known and still others are continually being identified. Pathogenic bacteria that can be utilized to deliver effector proteins or polypeptides are preferably disarmed according to known techniques, i.e., as described above. Alternatively, isolation of the effector protein or polypeptide from the host cell or growth medium can be carried out as described above.
Another aspect of the present invention relates to a transgenic plant which express a protein or polypeptide of the present invention and methods of making the same.
In order to express the DNA molecule in isolated plant cells or tissue or whole plants, a plant expressible promoter is needed. Any plant-expressible promoter can be utilized regardless of its origin, i.e., viral, bacterial, plant, etc. Without limitation, two suitable promoters include the nopaline synthase promoter (Fraley et al., 1983) and the cauliflower mosaic virus 35S promoter (O'Dell et al., 1985). Both of these promoters yield constitutive expression of coding sequences under their regulatory control.
While constitutive expression is generally suitable for expression of the DNA molecule, it should be apparent to those of skill in the art that temporally or tissue regulated expression may also be desirable, in which case any regulated promoter can be selected to achieve the desired expression. Typically, the temporally or tissue regulated promoters will be used in connection with the DNA molecule that are expressed at only certain stages of development or only in certain tissues.
In some plants, it may also be desirable to use promoters which are responsive to pathogen infiltration or stress. For example, it may be desirable to limit expression of the protein or polypeptide in response to infection by a particular pathogen of the plant. One example of a pathogen-inducible promoter is the gstl promoter from potato, which is described in U.S. Pat. Nos. 5,750,874 and 5,723,760 to Strittmayer et al., which are hereby incorporated by reference.
Expression of the DNA molecule in isolated plant cells or tissue or whole plants also requires appropriate transcription termination and polyadenylation of mRNA. Any 3′ regulatory region suitable for use in plant cells or tissue can be operably linked to the first and second DNA molecules. A number of 3′ regulatory regions are known to be operable in plants. Exemplary 3′ regulatory regions include, without limitation, the nopaline synthase 3′ regulatory region (Fraley et al., 1983) and the cauliflower mosaic virus 3′ regulatory region (Odell et al., 1985).
The promoter and a 3′ regulatory region can readily be ligated to the DNA molecule using well known molecular cloning techniques described in Sambrook et al., 1989.
One approach to transforming plant cells with a DNA molecule of the present invention is particle bombardment (also known as biolistic transformation) of the host cell. This can be accomplished in one of several ways. The first involves propelling inert or biologically active particles at cells. This technique is disclosed in U.S. Pat. Nos. 4,945,050, 5,036,006, and 5,100,792, all to Sanford, et al. Generally, this procedure involves propelling inert or biologically active particles at the cells under conditions effective to penetrate the outer surface of the cell and to be incorporated within the interior thereof. When inert particles are utilized, the vector can be introduced into the cell by coating the particles with the vector containing the heterologous DNA. Alternatively, the target cell can be surrounded by the vector so that the vector is carried into the cell by the wake of the particle. Biologically active particles (e.g., dried bacterial cells containing the vector and heterologous DNA) can also be propelled into plant cells. Other variations of particle bombardment, now known or hereafter developed, can also be used.
Another method of introducing the DNA molecule into plant cells is fusion of protoplasts with other entities, either minicells, cells, lysosomes, or other fusible lipid-surfaced bodies that contain the DNA molecule (Fraley et al., 1982).
The DNA molecule may also be introduced into the plant cells by electroporation (Fromm, et al., 1985). In this technique, plant protoplasts are electroporated in the presence of plasmids containing the DNA molecule. Electrical impulses of high field strength reversibly permeabilize biomembranes allowing the introduction of the plasmids. Electroporated plant protoplasts reform the cell wall, divide, and regenerate.
Another method of introducing the DNA molecule into plant cells is to infect a plant cell with Agrobacterium tumefaciens or Agrobacterium rhizogenes previously transformed with the DNA molecule. Under appropriate conditions known in the art, the transformed plant cells are grown to form shoots or roots, and develop further into plants. Generally, this procedure involves inoculating the plant tissue with a suspension of bacteria and incubating the tissue for 48 to 72 hours on regeneration medium without antibiotics at 25–28° C.
Agrobacterium is a representative genus of the Gram-negative family Rhizobiaceae. Its species are responsible for crown gall (A. tumefaciens) and hairy root disease (A. rhizogenes). The plant cells in crown gall tumors and hairy roots are induced to produce amino acid derivatives known as opines, which are catabolized only by the bacteria. The bacterial genes responsible for expression of opines are a convenient source of control elements for chimeric expression cassettes. In addition, assaying for the presence of opines can be used to identify transformed tissue.
Heterologous genetic sequences such as a DNA molecule of the present invention can be introduced into appropriate plant cells by means of the Ti plasmid of A. tumefaciens or the Ri plasmid of A. rhizogenes. The Ti or Ri plasmid is transmitted to plant cells on infection by Agrobacterium and is stably integrated into the plant genome (Schell, 1987).
Plant tissue suitable for transformation include leaf tissue, root tissue, meristems, zygotic and somatic embryos, and anthers.
After transformation, the transformed plant cells can be selected and regenerated.
Preferably, transformed cells are first identified using, e.g., a selection marker simultaneously introduced into the host cells along with the DNA molecule of the present invention. Suitable selection markers include, without limitation, markers coding for antibiotic resistance, such as kanamycin resistance (Fraley et al., 1983). A number of antibiotic-resistance markers are known in the art and other are continually being identified. Any known antibiotic-resistance marker can be used to transform and select transformed host cells in accordance with the present invention. Cells or tissues are grown on a selection media containing an antibiotic, whereby generally only those transformants expressing the antibiotic resistance marker continue to grow.
Once a recombinant plant cell or tissue has been obtained, it is possible to regenerate a full-grown plant therefrom. Thus, another aspect of the present invention relates to a transgenic plant that includes a DNA molecule of the present invention, wherein the promoter induces transcription of the first DNA molecule in response to infection of the plant by an oomycete. Preferably, the DNA molecule is stably inserted into the genome of the transgenic plant of the present invention.
Plant regeneration from cultured protoplasts is described in Evans et al., 1983, and Vasil, 1984 and 1986.
It is known that practically all plants can be regenerated from cultured cells or tissues, including but not limited to, all major species of rice, wheat, barley, rye, cotton, sunflower, peanut, corn, potato, sweet potato, bean, pea, chicory, lettuce, endive, cabbage, cauliflower, broccoli, turnip, radish, spinach, onion, garlic, eggplant, pepper, celery, carrot, squash, pumpkin, zucchini, cucumber, apple, pear, melon, strawberry, grape, raspberry, pineapple, soybean, tobacco, tomato, sorghum, and sugarcane.
Means for regeneration vary from species to species of plants, but generally a suspension of transformed protoplasts or a petri plate containing transformed explants is first provided. Callus tissue is formed and shoots may be induced from callus and subsequently rooted. Alternatively, embryo formation can be induced in the callus tissue. These embryos germinate as natural embryos to form plants. The culture media will generally contain various amino acids and hormones, such as auxin and cytokinins. It is also advantageous to add glutamic acid and proline to the medium, especially for such species as corn and alfalfa. Efficient regeneration will depend on the medium, on the genotype, and on the history of the culture. If these three variables are controlled, then regeneration is usually reproducible and repeatable.
After the DNA molecule is stably incorporated in transgenic plants, it can be transferred to other plants by sexual crossing or by preparing cultivars. With respect to sexual crossing, any of a number of standard breeding techniques can be used depending upon the species to be crossed. Cultivars can be propagated in accord with common agricultural procedures known to those in the field.
Diseases caused by the vast majority of bacterial pathogens result in limited lesions. That is, even when everything is working in the pathogen's favor (e.g., no triggering of the hypersensitive response because of R-gene detection of one of the effectors), the parasitic process still triggers defenses after a couple of days, which then stops the infection from spreading. Thus, the very same effectors that enable parasitism to proceed must also eventually trigger defenses. Therefore, premature expression of these effectors is believed to “turn on” plant defenses earlier (i.e., prior to infection) and make the plant resistant to either the specific bacteria from which the effector protein was obtained or many pathogens. An advantage of this approach is that it involves natural products and plants seem highly sensitive to pathogen effector proteins.
According to one embodiment, a transgenic plant is provided that contains a heterologous DNA molecule of the present invention. Preferably, the heterologous DNA molecule is derived from a plant pathogen EEL. When the heterologous DNA molecule is expressed in the transgenic plant, plant defenses are activated, imparting disease resistance to the transgenic plant. The transgenic plant can also contain an R-gene which is activated by the protein or polypeptide product of the heterologous DNA molecule. The R gene can be naturally occurring in the plant or heterologously inserted therein. A number of R genes have been identified in various plant species, including without limitation: RPS2, RPM1, and RPP5 from Arabidopsis thaliana; Cf2, Cf9, I2, Pto, and Prf from tomato; N from tobacco; L6 and M from flax; Xa21 from rice; and Hs1pro-1 from sugar beet. In addition to imparting disease resistance, it is believed that stimulation of plant defenses in transgenic plants of the present invention will also result in a simultaneous enhancement in growth and resistance to insects.
According to another embodiment, a plant, transgenic or non-transgenic, is treated with a protein or polypeptide of the present invention. By treating, it is intended to include various forms of applying the protein or polypeptide to the plant. The embodiments of the present invention where the effector polypeptide or protein is applied to the plant can be carried out in a number of ways, including: 1) application of an isolated protein (or composition containing the same) or 2) application of bacteria which do not cause disease and are transformed with a gene encoding the effector protein of the present invention. In the latter embodiment, the effector protein can be applied to plants by applying bacteria containing the DNA molecule encoding the effector protein. Such bacteria are preferably capable of secreting or exporting the protein so that the protein can contact plant cells. In these embodiments, the protein is produced by the bacteria in planta.
Such topical application is typically carried out using an effector fusion protein which includes a transduction domain, which will afford transduction domain-mediated spontaneous uptake of the effector protein into cells. Basically, this is carried out by fusing an 11-amino acid peptide (YGRKKRRQRRR, SEQ. ID. No. 91) by standard rDNA techniques to the N-terminus of the effector protein, and the resulting tagged protein is taken up into cells by a poorly understood process. This peptide is the protein transduction domain (PTD) of the human immunodeficiency virus (HIV) TAT protein (Schwarze et al., 2000). Other PTDs are known and may possibly be used for this purpose (Prochiantz, 2000).
When the effector protein is topically applied to plants, it can be applied as a composition, which includes a carrier in the form, e.g., of water, aqueous solutions, slurries, or dry powders. In this embodiment, the composition contains greater than about 5 nM of the protein of the present invention.
Although not required, this composition may contain additional additives including fertilizer, insecticide, fungicide, nematicide, and mixtures thereof. Suitable fertilizers include (NH4)2NO3. An example of a suitable insecticide is Malathion. Useful fungicides include Captan.
Other suitable additives include buffering agents, wetting agents, coating agents, and, in some instances, abrading agents. These materials can be used to facilitate the process of the present invention.
According to another aspect of the present invention, a transgenic plant is provided that contains a heterologous DNA molecule that encodes a transcript or a protein or polypeptide capable of disrupting function of a plant pathogen CEL product. Because the genes in the CEL are particularly important in pathogenesis, disrupting the function of their products in plants can result in broad resistance since CEL genes are highly conserved among Gram negative pathogens, particularly along species lines. An exemplary protein or polypeptide which can disrupt function of a CEL product is an antibody, polyclonal or monoclonal, raised against the CEL product using conventional techniques. Once isolated, the antibody can be sequenced and nucleic acids synthesized for encoding the same. Such nucleic acids, e.g., DNA, can be used to transform plants.
Transgenic plants can also be engineered so that they are hypersusceptible and, therefore, will support the growth of nonpathogenic bacteria for biotechnological purposes. It is known that many plant pathogenic bacteria can alter the environment inside plant leaves so that nonpathogenic bacteria can grow. This ability is presumably based on changes in the plant caused by pathogen effector proteins. Thus, transgenic plants expressing the appropriate effector genes can be used for these purposes.
According to one embodiment, a transgenic plant including a heterologous DNA molecule of the present invention expresses one or more effector proteins, wherein the transgenic plant is capable of supporting growth of compatible nonpathogenic bacteria (i.e., non-pathogenic endophytes such as various Clavibacter ssp.). The compatible nonpathogenic bacteria can be naturally occurring or it can be recombinant. Preferably, the nonpathogenic bacteria is recombinant and expresses one or more useful products. Thus, the transgenic plant becomes a green factory for producing desirable products. Desirable products include, without limitation, products that can enhance the nutritional quality of the plant or products that are desirable in isolated form. If desired in isolated form, the product can be isolated from plant tissues. To prevent competition between the non-pathogenic bacteria which express the desired product and those that do not, it is possible to tailor the needs of recombinant, non-pathogenic bacteria so that only they are capable of living in plant tissues expressing a particular effector protein or polypeptide of the present invention.
The effector proteins or polypeptides of the present invention are believed to alter the plant physiology by shifting metabolic pathways to benefit the parasite and by activating or suppressing cell death pathways. Thus, they may also provide useful tools for efficiently altering the nutrient content of plants and delaying or triggering senescence. There are agricultural applications for all of these possible effects.
A further aspect of the present invention relates to diagnostic uses of the CEL and EEL. The CEL genes are universal to species of Gram negative bacteria, particularly pathogenic Gram negative bacteria (such as P. syringae), whereas the EEL sequences are strain-specific and provide a “virulence gene fingerprint” that could be used to track the presence, origins, and movement (and restrict the spread through quarantines) of strains that are particularly threatening. Although the CEL and EEL have been identified in various pathovars of Pseudomonas syringae, it is expected that most all Gram-negative pathogens can be identified, distinguished, and classified based upon the homology of the CEL and EEL genes.
According to one embodiment, a method of determining relatedness between two bacteria is carried out by comparing a nucleic acid alignment or amino acid alignment for a CEL of the two bacteria and then determining the relatedness of the two bacteria, wherein a higher sequence identity indicates a closer relationship. The CEL is particularly useful for determining the relatedness of two distinct bacterial species.
According to another embodiment, a method of determining relatedness between two bacteria which is carried out by comparing a nucleic acid alignment or amino acid alignment for an EEL of the two bacteria and then determining the relatedness of the two bacteria, wherein a higher sequence identity indicates a closer relationship. The EEL is particularly useful for determining the relatedness of two pathovars of a single bacterial species.
Given the methods of determining relatedness of bacteria species and/or pathovars, these methods can be utilized in conjunction with plant breeding programs. By detecting the “virulence gene fingerprint” of pathogens which are prevalent in a particular growing region, it is possible either to develop transgenic cultivars as described above or to identify existing plant cultivars which are resistant to the prevalent pathogens.
In addition to the above described uses, another aspect of the present invention relates to gene- and protein-based therapies for animals, preferably mammals including, without limitation, humans, dogs, mice, rats. The P. syringae pv. syringae B728a EEL ORF5 protein (SEQ. ID. No. 32) is a member of the AvrRxv/YopJ protein family. YopJ is injected into human cells by the Yersinia type III secretion system, where it disrupts the function of certain protein kinases to inhibit cytokine release and promote programmed cell death. It is believed that the targets of many pathogen effector proteins (i.e., P. syringae effector proteins) will be universal to eukaryotes and therefore have a variety of potentially useful functions. In fact, two of the proteins in the P. syringae Hrp pathogenicity islands are toxic when expressed in yeast. They are HopPsyA from the P. syringae pv. syringae EEL and HopPtoA from the P. syringae pv. tomato DC3000 CEL. This supports the concept of universal eukaryote targets.
Thus, a further aspect of the present invention relates to a method of causing eukaryotic cell death which is carried out by introducing into a eukaryotic cell a cytotoxic Pseudomonas protein. The cytotoxic Pseudomonas protein is preferably HopPsyA (e.g., SEQ. ID. Nos. 36 (Psy 61), 62 (Psy 226), or 64 (Psy B143)) HopPtoA (SEQ. ID. No. 7), or HopPtoA2 (SEQ. ID. No. 66). The eukaryotic cell which is treated can be either in vitro or in vivo. When treating eukaryotic cells in vivo, a number of different protein- or DNA-delivery systems can be employed to introduce the effector protein into the target eukaryotic cell.
Without being bound by theory, it is believed that at least the HopPsyA effector proteins exert their cytotoxic effects through Mad2 interactions, disrupting cell checkpoint of spindle formation (see infra).
The protein- or DNA-delivery systems can be provided in the form of pharmaceutical compositions which include the delivery system in a pharmaceutically acceptable carrier, which may include suitable excipients or stabilizers. The dosage can be in solid or liquid form, such as powders, solutions, suspensions, or emulsions. Typically, the composition will contain from about 0.01 to 99 percent, preferably from about 20 to 75 percent of active compound(s), together with the carrier, excipient, stabilizer, etc.
The compositions of the present invention are preferably administered in injectable or topically-applied dosages by solution or suspension of these materials in a physiologically acceptable diluent with a pharmaceutical carrier. Such carriers include sterile liquids, such as water and oils, with or without the addition of a surfactant and other pharmaceutically and physiologically acceptable carrier, including adjuvants, excipients or stabilizers. Illustrative oils are those of petroleum, animal, vegetable, or synthetic origin, for example, peanut oil, soybean oil, or mineral oil. In general, water, saline, aqueous dextrose and related sugar solution, and glycols, such as propylene glycol or polyethylene glycol, are preferred liquid carriers, particularly for injectable solutions.
Alternatively, the effector proteins can also be delivered via solution or suspension packaged in a pressurized aerosol container together with suitable propellants, for example, hydrocarbon propellants like propane, butane, or isobutane with conventional adjuvants. The materials of the present invention also may be administered in a non-pressurized form such as in a nebulizer or atomizer.
Depending upon the treatment being effected, the compounds of the present invention can be administered orally, topically, transdermally, parenterally, subcutaneously, intravenously, intramuscularly, intraperitoneally, by intranasal instillation, by intracavitary or intravesical instillation, intraocularly, intraarterially, intralesionally, or by application to mucous membranes, such as, that of the nose, throat, and bronchial tubes.
Compositions within the scope of this invention include all compositions wherein the compound of the present invention is contained in an amount effective to achieve its intended purpose. While individual needs vary, determination of optimal ranges of effective amounts of each component is within the skill of the art.
One approach for delivering an effector protein into cells involves the use of liposomes. Basically, this involves providing a liposome which includes that effector protein to be delivered, and then contacting the target cell with the liposome under conditions effective for delivery of the effector protein into the cell.
Liposomes are vesicles comprised of one or more concentrically ordered lipid bilayers which encapsulate an aqueous phase. They are normally not leaky, but can become leaky if a hole or pore occurs in the membrane, if the membrane is dissolved or degrades, or if the membrane temperature is increased to the phase transition temperature. Current methods of drug delivery via liposomes require that the liposome carrier ultimately become permeable and release the encapsulated drug at the target site. This can be accomplished, for example, in a passive manner wherein the liposome bilayer degrades over time through the action of various agents in the body. Every liposome composition will have a characteristic half-life in the circulation or at other sites in the body and, thus, by controlling the half-life of the liposome composition, the rate at which the bilayer degrades can be somewhat regulated.
In contrast to passive drug release, active drug release involves using an agent to induce a permeability change in the liposome vesicle. Liposome membranes can be constructed so that they become destabilized when the environment becomes acidic near the liposome membrane (see, e.g., Proc. Natl. Acad. Sci. USA 84:7851 (1987); Biochemistry 28:908 (1989), which are hereby incorporated by reference). When liposomes are endocytosed by a target cell, for example, they can be routed to acidic endosomes which will destabilize the liposome and result in drug release.
Alternatively, the liposome membrane can be chemically modified such that an enzyme is placed as a coating on the membrane which slowly destabilizes the liposome. Since control of drug release depends on the concentration of enzyme initially placed in the membrane, there is no real effective way to modulate or alter drug release to achieve “on demand” drug delivery. The same problem exists for pH-sensitive liposomes in that as soon as the liposome vesicle comes into contact with a target cell, it will be engulfed and a drop in pH will lead to drug release.
This liposome delivery system can also be made to accumulate at a target organ, tissue, or cell via active targeting (e.g., by incorporating an antibody or hormone on the surface of the liposomal vehicle). This can be achieved according to known methods.
Different types of liposomes can be prepared according to Bangham et al., (1965); U.S. Pat. No. 5,653,996 to Hsu et al., U.S. Pat. No. 5,643,599 to Lee et al.; U.S. Pat. No. 5,885,613 to Holland et al.; U.S. Pat. No. 5,631,237 to Dzau et al.; and U.S. Pat. No. 5,059,421 to Loughrey et al.
An alternative approach for delivery of effector proteins involves the conjugation of the desired effector protein to a polymer that is stabilized to avoid enzymatic degradation of the conjugated effector protein. Conjugated proteins or polypeptides of this type are described in U.S. Pat. No. 5,681,811 to Ekwuribe.
Yet another approach for delivery of proteins or polypeptides involves preparation of chimeric proteins according to U.S. Pat. No. 5,817,789 to Heartlein et al. The chimeric protein can include a ligand domain and, e.g., an effector protein of the present invention. The ligand domain is specific for receptors located on a target cell. Thus, when the chimeric protein is delivered intravenously or otherwise introduced into blood or lymph, the chimeric protein will adsorb to the targeted cell, and the targeted cell will internalize the chimeric protein, which allows the effector protein to de-stabilize the cell checkpoint control mechanism, affording its cytotoxic effects.
When it is desirable to achieve heterologous expression of an effector protein of the present invention in a target cell, DNA molecules encoding the desired effector protein can be delivered into the cell. Basically, this includes providing a nucleic acid molecule encoding the effector protein and then introducing the nucleic acid molecule into the cell under conditions effective to express the effector protein in the cell. Preferably, this is achieved by inserting the nucleic acid molecule into an expression vector before it is introduced into the cell.
When transforming mammalian cells for heterologous expression of an effector protein, an adenovirus vector can be employed. Adenovirus gene delivery vehicles can be readily prepared and utilized given the disclosure provided in Berkner, 1988, and Rosenfeld et al., 1991. Adeno-associated viral gene delivery vehicles can be constructed and used to deliver a gene to cells. The use of adeno-associated viral gene delivery vehicles in vitro is described in Chatterjee et al. 1992; Walsh et al. 1992; Walsh et al., 1994; Flotte et al., 1993a; Ponnazhagan et al., 1994; Miller et al., 1994; Einerhand et al., 1995; Luo et al., 1995; and Zhou et al., 1996. In vivo use of these vehicles is described in Flotte et al., 1993b and Kaplitt et al., 1994. Additional types of adenovirus vectors are described in U.S. Pat. No. 6,057,155 to Wickham et al.; U.S. Pat. No. 6,033,908 to Bout et al.; U.S. Pat. No. 6,001,557 to Wilson et al.; U.S. Pat. No. 5,994,132 to Chamberlain et al.; U.S. Pat. No. 5,981,225 to Kochanek et al.; U.S. Pat. No. 5,885,808 to Spooner et al.; and U.S. Pat. No. 5,871,727 to Curiel.
Retroviral vectors which have been modified to form infective transformation systems can also be used to deliver nucleic acid encoding a desired effector protein into a target cell. One such type of retroviral vector is disclosed in U.S. Pat. No. 5,849,586 to Kriegler et al.
Regardless of the type of infective transformation system employed, it should be targeted for delivery of the nucleic acid to a specific cell type. For example, for delivery of the nucleic acid into tumor cells, a high titer of the infective transformation system can be injected directly within the tumor site so as to enhance the likelihood of tumor cell infection. The infected cells will then express the desired effector protein, e.g., HopPtoA, HopPsyA, or HopPtoA2, disrupting cellular functions and producing cytotoxic effects.
Particularly preferred is use of the effector proteins of the present invention to treat a cancerous condition (i.e., the eukaryotic cell which is affected is a cancer cell). This can be carried out by introducing a cytotoxic Pseudomonas protein into cancer cells of a patient under conditions effective to inhibit cancer cell division, thereby treating the cancerous condition.
By introducing, it is intended that the effector protein is administered to the patient, preferably in the form of a composition which will target delivery to the cancer cells. Alternatively, when using DNA-based therapies, it is intended that the introducing be carried out by administering a target DNA delivery system to the patient such that the cancer cells are targeted and the effector protein is expressed therein.
The following Examples are intended to be illustrative and in no way are intended to limit the scope of the present invention.
Materials and Methods
Bacterial Strains, Culture Conditions, Plasmids, and DNA Manipulation Techniques:
Three experimentally amenable strains that represent different levels of diversity in P. syringae were investigated: Psy 61, Psy B728a, and Pto DC3000. (i) Psy 61 is a weak pathogen of bean whose hrp gene cluster, cloned on cosmid pHIR11, contains all of the genes necessary for nonpathogenic bacteria like Pseudomonas fluorescens and Escherichia coli to elicit the HR in tobacco and to secrete in culture the HrpZ harpin, a protein with unknown function that is secreted abundantly by the Hrp system (Alfano et al., 1996). The pHIR11 hrp cluster has been completely sequenced (
Conditions for culturing E. coli and P. syringae strains have been described (van Dijk et al., 1999), as have the sources for Psy 61 (Preston et al., 1995), Psy B728a (Hirano et al., 1999), and Pto DC3000 (Preston et al., 1995). Cloning and DNA manipulations were done in E. coli DH5α using pBluescript II (Stratagene, La Jolla, Calif.), pRK415 (Keen et al., 1988), and cosmid pCPP47 (Bauer and Collmer, 1997), according to standard procedures (Ausubel et al., 1994). Cosmid libraries of Pto DC3000 and Psy B728a genomic DNA were previously constructed (Charkowski et al., 1998). Oligonucleotide synthesis and DNA sequencing were performed at the Cornell Biotechnology Center. The nucleotide sequence of the Pto DC3000 hrp/hrc cluster was determined using subclones of pCPP2473, a cosmid selected from a genomic cosmid library based on hybridization with the hrpK gene of Psy 61. The nucleotide sequence of the Psy B728a hrp/hrc cluster was determined using subclones of pCPP2346 and pCPP3017. These cosmids were selected from a genomic library based on hybridization with the hrpC operon of 61. The left side of the Psy 61 EEL region was cloned by PCR into pBSKSII+ XhoI and EcoRI sites using the following primers:
SEQ. ID. NO. 71, which primes within queA and contains an XhoI site:
SEQ. ID. NO. 72, which primes within hopPsyA and contains an EcoRI site:
Pfu polymerase was used for all PCR experiments. DNA sequence data were managed and analyzed with the DNAStar Program (Madison, Wis.), and databases were searched with the BLASTX, BLASTP, and BLASTN programs (Altschul et al., 1997).
Mutant Construction and Analysis:
Large deletions in the Pto DC3000 Hrp Pai were constructed by subcloning border fragments into restriction sites on either side of an ΩSpR cassette in pRK415, electroporating the recombinant plasmids into DC3000, and then selecting and screening for marker exchange mutants as described (Alfano et al., 1996). The following left and right side (
SEQ. ID. NO. 73, which primes in the ORF5–ORF6 intergenic region and contains an XbaI site:
SEQ. ID. NO. 74, which primes in ORF6 and contains a HindIII site:
Mutant constructions were confirmed by Southern hybridizations using previously described conditions (Charkowski et al., 1998). The ability of mutants to secrete AvrPto was determined with anti-AvrPto antibodies and immunoblot analysis of cell fractions as previously described (van Dijk et al., 1999). Mutant CUCPB5115 was complemented with pCPP3016, which carries ORF2 through ORF10 in cosmid pCPP47, and was introduced from E. coli DH5α by triparental mating using helper strain E. coli DH5α(pRK600), as described (Charkowski et al., 1998).
T7 Expression Analysis:
Protein products of the Pto DC3000 EEL were analyzed by T7 polymerase-dependent expression using vector pET21 and E. coli BL21(DE3) as previously described (Huang et al., 1995). The following primer sets were used to PCR each ORF from pCPP3091, which carries in pBSKSII+ a BamH1 fragment containing tgt to hrcV:
ORF1, SEQ. ID. Nos. 75 and 76, respectively:
ORF2, SEQ. ID. Nos. 77 and 78, respectively:
ORF3, SEQ. ID. Nos. 79 and 80, respectively:
ORF4, SEQ. ID. Nos. 81 and 82, respectively:
tnpA, SEQ. ID. Nos. 83 and 84, respectively:
Plant Bioassays:
Tobacco (Nicotiana tabacum L. cv. Xanthi) and tomato (Lycopersicon esculentum Mill. cvs. Moneymaker and Rio Grande) were grown under greenhouse conditions and then maintained at 25° C. with daylight and supplemental halide illumination for HR and virulence assays. Bacteria were grown overnight on King's medium B agar supplemented with appropriate antibiotics, suspended in 5 mM MES pH 5.6, and then infiltrated with a needleless syringe into the leaves of test plants at 108 cfu/ml for HR assays and 104 cfu/ml for pathogenicity assays (Charkowski et al., 1998). All assays were repeated at least four times on leaves from different plants. Bacterial growth in tomato leaves was assayed by excising disks from infiltrated areas with a cork borer, comminuting the tissue in 0.5 ml of 5 mM MES, pH 5.6, with a Kontes Pellet Pestle (Fisher Scientific, Pittsburgh, Pa.), and then dilution plating the homogenate on King's medium B agar with 50 μg/ml rifampicin and 2 μg/ml cycloheximide to determine bacterial populations. The mean and SD from three leaf samples were determined for each time point. The relative growth in planta of DC3000 and CUCPB5110 was similarly assayed in 4 independent experiments and the relative growth of DC3000, CUCPB5115, and CUCPB5115(pCPP3016) in 3 independent experiments. Although the final population levels achieved by DC3000 varied between experiments, the populations levels of the mutants relative to the wild type were the same as in the representative experiments presented below.
Comparison of hrp/hrc Gene Clusters of Psy 61, Psy B728a, and Pto DC3000
To determine if the hrp/hrc clusters from Psy B728a and Pto DC3000 were organized similarly to the previously characterized hrp/hrc cluster of Psy 61, two cosmids carrying hrp/hrc inserts were partially characterized. pCPP2346 carries the entire hrp/hrc cluster of B728a, and pCPP2473 carries the left half of the hrp/hrc cluster of DC3000. The right half of the DC3000 hrp/hrc cluster had been characterized previously (Preston et al., 1995). Sequencing the ends of several subclones derived from these cosmids provided fingerprints of the B728a and DC3000 hrp/hrc clusters, which indicated that both are arranged like that of strain 61 (
Identification of an Exchangeable Effector Locus (EEL) in the Hrp Pai between hrpK and tRNALeu
Sequence analysis of the left side of the Psy 61, Psy B728a, and Pto DC3000 Hrp Pais revealed that the high percentage identity in hrpK sequences in these strains abruptly terminates three nucleotides after the hrpK stop codon and then is restored near tRNALeu, queA, and tgt sequences after 2.5 kb (Psy 61), 7.3 kb (Psy B728a), or 5.9 kb (Pto DC3000) of dissimilar, intervening DNA (
The EELs of these three strains also contain sequences homologous to insertion sequences, transposases, phage integrase genes, and plasmids (
aPathovar abbreviations correspond to the recommendations of Vivian and Mansfield (1993) for uniform avr nomenclature.
The left border of the EELs contains sequences similar to many tRNALeu genes and to E. coli queA and tgt queuosine biosynthesis genes (ca. 70% amino-acid identity in predicted products). The EEL sequences terminate at the 3′ end of the P. syringae tRNA sequences, as is typical for Pais (Hou, 1999). Virtually identical tgt-queA-tRNALeu sequences are found in the genome of P. aeruginosa PAO1 (www.pseudomonas.com), which is also in the fluorescent pseudomonad group. But PAO1 is not a plant pathogen, and this tRNALeu in P. aeruginosa is not linked to any type III secretion system genes or other genes in the Hrp Pai (
Identification of a Conserved Effector Locus (CEL) Located on the Right Side of the Hrp Pai in Psy B728a and Pto DC3000
Previous studies of the region to the right of hrpR in DC3000 had revealed the existence of the avrE locus, which is comprised of two transcriptional units (Lorang and Keen, 1995), the 5′ sequences for the first 4 transcriptional units beyond hrpR (Lorang and Keen, 1995), and the identity of the fourth transcriptional unit as the hrpW gene encoding a second harpin (Charkowski et al., 1998). The DNA sequence of the first 14 ORFs to the right of hrpR in Pto DC3000 was completed in this investigation and the corresponding region in Psy B728a was partially sequenced (
The precise border of the CEL remains undefined, and no sequences that were repeated in the EEL border of the Hrp Pai were found. ORF7 and ORF8 are likely to be part of the CEL, based on the presence of an upstream Hrp box (
Several other features of this region in B728a and DC3000 are noteworthy. (i) Both strains have a 1-kb intergenic region between hrpR and ORF1 that is distinguished by low sequence identity (44%) but which contains three inverted repeats that could form stem loop structures affecting expression of the hrpRS operon. (ii) ORF1 is most similar to E. coli murein lytic transglycosylase MltD (38% identity over 324 amino acids; E=4e-56). (iii) ORF2 is 42% identical over 130 amino acids with E. amylovora DspF (E=9e-24), a candidate chaperone (Bogdanove et al., 1998a; Gaudriault et al., 1997). (iv) The ORF5 protein is secreted in a hrp-dependent manner by E. coli(pCPP2156), but mutation with an ΩSpr cassette has little effect on either HR elicitation in tobacco or pathogenicity in tomato (Charkowski, unpublished). (v) Finally, six operons in this region are preceded by Hrp boxes (Lorang and Keen, 1995) (
Investigation of EEL and CEL Roles in Pathogenicity
A mutation was constructed in DC3000 that replaced all of the ORFs between hrpK and tRNALeu (EEL) with an ΩSpr cassette (
A mutation was constructed in DC3000 that replaced avrE through ORF5 (CEL) with an ΩSpr cassette. This deleted all of the CEL ORFs that were both partially characterized and likely to encode effectors. This Pto mutant, CUCPB5115, still elicited the HR in tobacco, but tissue collapse was delayed ca. 5 h (
Based on the above studies, the P. syringae hrp/hrc genes are part of a Hrp Pai that has three distinct loci: an EEL, the hrp/hrc gene cluster, and a CEL. The EEL harbors exchangeable effector genes and makes only a quantitative contribution to parasitic fitness in host plants. The hrp/hrc locus encodes the Hrp secretion system and is required for effector protein delivery, parasitism, and pathogenicity. The CEL makes no discernible contribution to Hrp secretion functions but contributes strongly to parasitic fitness and is required for Pto pathogenicity in tomato. The Hrp Pai of P. syringae has several properties of Pais possessed by animal pathogens (Hacker et al., 1997), including the presence of many virulence-associated genes (several with relatively low G+C content) in a large (ca. 50-kb) chromosomal region linked to a tRNA locus and absent from the corresponding locus in a closely related species. In addition, the EEL portion of the Hrp Pai is unstable and contains many sequences related to mobile genetic elements.
The EEL is a novel feature of known Pais, which is likely involved in fine-tuning the parasitic fitness of P. syringae strains with various plant hosts. By comparing closely- and distantly-related strains of P. syringae, we were able to establish the high instability of this locus and the contrasting high conservation of its border sequences. No single mechanism can explain the high instability, as we found fragments related to phages, insertion sequences, and plasmids in the Psy and Pto EELs, and insertion sequences were recently reported in the corresponding region of three other P. syringae strains (Inoue and Takikawa, 1999). The mechanism or significance of the localization of the EELs between tRNALeu and hrpK sequences in the Hrp Pais also is unclear. Pto DC3000 carries at least one other effector gene, avrPto, that is located elsewhere in the genome (Ronald et al., 1992), many P. syringae avr genes are located on plasmids (Leach and White, 1996), and the EEL ORFs represent a mix of widespread, (e.g., avrRxv family) and seemingly rare (e.g., hopPsyA), effector genes. The G+C content of the EEL ORFs is significantly lower than that of the rest of the Hrp Pai and the P. syringae genome. Although certain genes in the non-EEL portions of the Hrp Pai, such as hrpA, are highly divergent, they have a high G+C content, and there is no evidence that they have been horizontally transferred separately from the rest of the Hrp Pai. The relatively low G+C content of the ORFs in the EELs (and of other P. syringae avr genes) suggests that these genes may be horizontally acquired from a wider pool of pathogenic bacteria than just P. syringae (Kim et al., 1998). Indeed, the avrRxv family of genes is found in a wide range of plant and animal pathogens (Ciesiolka et al., 1999). The weak effect on parasitic fitness of deleting the Pto DC3000 EEL, or of mutating hopPsyA (hrmA) in Psy 61 (Huang et al., 1991), is typical of mutations in individual avr genes and presumably results from redundancy in the effector protein system (Leach and White, 1996).
The functions of hrpK and of the CEL ORF1 are unclear but warrant discussion. These two ORFs reside just outside the hrpL and hrpR delimited cluster of operons containing both hrp and hrc genes and thereby spatially separate the three regions of the Hrp Pai (
The loss of pathogenicity in Pto mutant CUCPB5115, with an avrE-ORF5 deletion in the CEL, was surprising because pathogenicity is retained in DC3000 mutants in which the corresponding operons are individually disrupted (Lorang and Keen, 1995; Charkowski et al., 1998). In assessing the possible function of this region and the conservation of its constituent genes, it should be noted that avrE is unlike other avr genes found in Pto in that it confers avirulence to P. syringae pv glycinea on all tested soybean cultivars and it has a homolog (dspE) in E. amylovora that is required for pathogenicity (Lorang and Keen, 1995; Bogdanove et al., 1998b). Although the CEL is required for pathogenicity, it is not essential for type III effector protein secretion because the mutant still secretes AvrPto. It also appears to play no essential role in type III translocation of effector proteins into plant cells because the mutant still elicits the HR in nonhost tobacco and in a PtoR-resistance tomato line, and pHIR11, which lacks this region, appears capable of translocating several Avr proteins (Gopalan et al., 1996; Pirhonen et al., 1996). The conservation of this region in the divergent pathovars Psy and Pto, and its importance in disease, suggests that the products of the CEL may be redundantly involved in a common, essential aspect of pathogenesis.
The similar G+C content and codon usage of the hrp/hrc genes, the genes in the CEL, and total P. syringae genomic DNA suggests that the Hrp Pai was acquired early in the evolution of P. syringae. Although, the EEL region may have similarly developed early in the radiation of P. syringae into its many pathovars, races, and strains, the apparent instability that is discussed above suggests ongoing rapid evolution at this locus. Indeed, many P. syringae avr genes are associated with mobile genetic elements, regardless of their location (Kim et al., 1998). Thus, it appears that Hrp-mediated pathogenicity in P. syringae is collectively dependent on a set of genes that are universal among divergent pathovars and on another set that varies among strains even in the same pathovar. The latter are presumably acquired and lost in response to opposing selection pressures to promote parasitism while evading host R-gene surveillance systems.
Role of ShcA as a Type III Chaperone for the HopPsyA Effector
The ORF upstream of hopPsyA, tentatively named shcA, encodes a protein product of the predicted molecular mass. The ORF upstream of the hopPsyA gene in P. s. syringae 61 (originally designated ORF1) shares sequence identity with exsC and ORF7, which are genes adjacent to type III effector genes in P. aeruginosa and Yersinia pestis, respectively (Frank and Iglewski, 1991; Perry et al., 1998). Although neither of these ORFs have been shown experimentally to encode chaperones, they have been noted to share properties that type III chaperones often possess (Cornellis et al., 1998). One of these properties is the location of the chaperone gene itself (
To test the effects of shcA on bacterial-plant interactions, an shcA mutation was constructed in the minimalist hrp/hrc cluster carried on cosmid pHIR11. There are distinct advantages to having the shcA mutation marker-exchanged into pHIR11. The main one is that the HR assay can be used as a screen to determine if HopPsyA is being translocated into plant cells because the pHIR11-dependent HR requires the delivery of HopPsyA into plant cells (Alfano et al., 1996; Alfano et al., 1997). With the chromosomal shcA mutant, other Hop proteins would probably be delivered to the interior of plant cells. Some of these proteins would be recognized by the R gene-based plant surveillance system and initiate an HR masking any defect in HopPsyA delivery. E. coli MC4100 carrying pLV10, a pHIR11 derivative, which contains a nonpolar nptII cartridge within shcA, was unable to elicit an HR on tobacco (
Cytotoxic Effects of hopPsyA Expressed in Plants
Transient expression of hopPsyA DNA in planta induces cell death in Nicotiana tabacum, but not in N. benthamiana, bean, or in Arabidopsis. To determine whether HopPsyA induced cell death on tobacco leaves as it did when produced in tobacco suspension cells, a transformation system that delivers the hopPsyA gene on T-DNA of Agrobacterium tumefaciens was used (Rossi et al., 1993; van den Ackerveken et al., 1996). This delivery system works better than biolistics for transiently transforming whole plant leaves. For these experiments, vector pTA7002, kindly provided by Nam-Hai Chua and his colleagues at Rockefeller University, was used. The unique property of this vector is that it contains an inducible expression system that uses the regulatory mechanism of the glucocorticoid receptor (Picard et al., 1988; Aoyama and Chua, 1997; McNellis et al., 1998). pTA7002 encodes a chimeric transcription factor consisting of the DNA-binding domain of GAL4, the transactivating domain of the herpes viral protein VP16, and the receptor domain of the rat glucocorticoid receptor. Also contained on this vector is a promoter containing GAL4 upstream activating sequences (UAS) upstream of a multiple cloning site. Thus, any gene cloned downstream of the promoter containing the GAL4-UAS is induced by glucocorticoids, of which a synthetic glucocorticoid, dexamethasone (DEX), is available commercially. hopPsyA was PCR-cloned downstream of the GAL4-UAS. Plant leaves from several different test plants were infiltrated with Argrobacterium carrying pTA7002::hopPsyA and after 48 hours these plants were sprayed with DEX. Only N. tabacum elicited an HR in response to the DEX-induced transient expression of hopPsyA (
P.s. pv. syringae 61 secretes HopPsyA in culture via the Hrp (type III) protein secretion system. Because the P. syringae Avr proteins AvrB and AvrPto were found to be secreted by the type III secretion system encoded by the functional E. chrysanthemi hrp cluster carried on cosmid pCPP2156 expressed in E. coli (Ham et al., 1998), detection of HopPsyA secretion in culture directly via the native Hrp system carried in P. s. syringae 61 was tested. P. s. syringae 61 cultures grown in hrp-derepressing fructose minimal medium at 22° C. were separated into cell-bound and supernatant fractions by centrifugation. Proteins present in the supernatant fractions were concentrated by TCA precipitation, and the cell-bound and supernatant samples were resolved with SDS-PAGE and analyzed with immunoblots using anti-HopPsyA antibodies. A HopPsyA signal was detected in supernatant fractions from wild type P. s. syringae 61 (
HopPsyA contributes in a detectable, albeit minor, way to growth of P. s. syringae 61 in bean. The effect of a HopPsyA mutation on the multiplication of P. s. syringae 61 in bean tissue has been reported (Huang et al., 1991). These data essentially indicate that HopPsyA contributes little to the ability of P. s. syringae 61 to multiply in bean. The P. s. syringae 61 hopPsyA mutant does not grow as well in bean leaves as the wild-type strain (
Molecular Interactions of HopPsyA
HopPsyA interacts with the Arabidopsis Mad2 protein in the yeast 2-hybrid system. To determine a pathogenic target for HopPsyA, the yeast 2-hybrid system was used with cDNA libraries made from Arabidopsis (Fields and Song, 1989; Finley and Brent, 1994). In the yeast 2-hybrid system, a fusion between the protein of interest (the “bait”) and the LexA DNA-binding domain was transformed into a yeast tester strain. A cDNA expression library was constructed in a vector that creates fusions to a transcriptional activator domain. This library was transformed into the tester strain en masse, and clones encoding partners for the “bait” are selected via their ability to bring the transcriptional activator domain into proximity with the DNA binding domain, thus initiating transcription of the LEU2 selectable marker gene. A second round screening of candidates, that activate the LEU2 marker, relies on their ability to also activate a lacZ reporter gene. Bait constructs were initially made with hopPsyA in the yeast vector pEG202 that corresponded to a full-length HopPsyA-LexA fusion, the carboxy-terminal half of HopPsyA fused to LexA, and the amino-terminal half of HopPsyA fused to LexA, and named these constructs pLV23, pLV24, and pLV25, respectively. However, pLV23 was lethal to yeast and pLV25 activated the lacZ reporter gene in relatively high amounts on its own (i.e., without the activation domain present). Thus, both pLV23 and pLV25 were not used to screen for protein interactors via the yeast 2-hybrid system. pLV24, which contains the 3′ portion of hopPsyA fused to lexA, proved to be an appropriate construct to use for bait in the yeast 2-hybrid system, because it did not autoactivate the lacZ reporter gene and, based on the lacZ repression assay using pJK101, the ‘HopPsyA-LexA fusion produced by pLV24 appeared to localize to the nucleus. In addition, it was confirmed that pLV24 made a protein of the appropriate size that corresponds to HopPsyA by performing immunoblots with anti-HopPsyA antibodies on yeast cultures carrying this vector.
Initial screens with pLV24 and Arabidopsis cDNA libraries in the yeast 2-hybrid vector pJG4-5. From three independent screens, several hundred putative interactors with HopPsyA were identified, each activating the two reporter systems to varying degrees. When these putative positive yeast strains were rescreened and criteria were limited to interactors that strongly induced both the lacZ reporter and LEU2 gene in the presence of galactose, about 50 yeast strains were identified that appeared to contain pJG4-5 derivatives that encoded proteins that could interact with the C-terminal half of HopPsyA. DNA gel blots using PCR-amplified inserts from selected pJG4-5 derivatives as probes allowed each of these putative positives to be grouped. Approximately 50% of the pJG4-5 derivatives that encoded strong HopPsyA interactors belonged to the same group. A pJG4-5 derivative containing this insert, pLV116 was sequenced. The predicted amino acid sequence of the insert contained within pLV116 shared high amino acid identity to Mad2 homologs (for mitotic arrest deficient) found in yeast, humans, frogs, and corn. Moreover, based on amino acid comparison with the other Mad2 proteins, pLV116 contains a cDNA insert that corresponds to the full-length mad2 mRNA. Table 2 below shows the amino acid percent identity of all of the Mad2 homologs currently in the databases.
Arabi-
dopsis
Arabidopsis
Not unexpectedly, the sequence of the Arabidopsis Mad2 protein is more closely related to the corn Mad2, the only plant Mad2 homolog represented in the databases. The corn Mad2 is about 82% identical to the Arabidopsis Mad2.
The above results are very promising, because Mad2 is a regulator controlling the transition from metaphase to anaphase during mitosis, a key step in the cell cycle of eukaryotes. The eukaryotic cell cycle is dependent on the completion of earlier events before another phase of the cell cycle can be initiated. For example, before mitosis can occur DNA replication has to be completed. Some of these dependencies in the cell cycle can be relieved by mutations and represent checkpoints that insure the cell cycle is proceeding normally (Hartwell and Weinert, 1989). In pioneering work, Hoyt et al. and Li and Murray independently discovered that there is a checkpoint in place in Saccharomyces cerevisiae to monitor whether the spindle assembly required for chromosome segregation is completed (Hoyt et al., 1991; Li and Murray, 1991). This so-called spindle checkpoint was discovered when the observation was made that wild-type yeast cells plated onto media containing drugs that disrupt microtubule polymerization arrested in mitosis, whereas certain mutants proceeded into anaphase. These initial reports identified 6 different nonessential genes that are involved in the spindle checkpoint: bub1–3 named for budding uninhibited by benzimidazole and mad1–3 for mitotic arrest deficient. Mutations in these genes ignore spindle assembly abnormalities and attempt mitosis regardless. In the years since, the spindle checkpoint has been shown to be conserved in other eukaryotes and many advances have occurred resulting in a better picture of what is taking place at the spindle checkpoint (Glotzer, 1996; Rudner and Murray, 1996).
Required for the transition from metaphase to anaphase (as well as other cell cycle transitions) is the ubiquitin proteolysis pathway. Proteins that inhibit entry into anaphase (e.g., Pds1 in S. cerevisiae) are tagged for degradation via the ubiquitin pathway by the anaphase-promoting complex (APC) (King et al., 1996). Only when these proteins are degraded by the 26S proteosome are the cells allowed to cycle to anaphase. Although it is not well understood how the APC knows when to tag the anaphase inhibitors for degradation, there have been several important advances (Elledge, 1996; Elledge, 1998; Hardwick, 1998). The Mad2 protein and the Bub1 protein kinase have been shown to bind to kinetochores when these regions are not attached to microtubules (Chen et al., 1996; Li and Benezra, 1996; Taylor and McKeon, 1997; Yu et al., 1999). Thus, these proteins appear to somehow relay a signal that all of the chromosomes are not bound to spindle fibers ready to separate. Mad1 encodes a phosphoprotein, which becomes hyperphosphorylated when the spindle checkpoint is activated and the hyperphosphorylation of Mad1 is dependent on functional Bub1, Bub3, and Mad2 proteins (Hardwick and Murray, 1995). Another required protein in this checkpoint is Mps1, a protein kinase that activates the spindle checkpoint when overexpressed in a manner that is dependent on all of the Bub and Mad proteins, indicating that Mps1 acts very early in the spindle checkpoint (Hardwick et al., 1996).
Based on data from the different Mad2 homologs that have been studied, Mad2 appears to have a central role in the spindle checkpoint. Addition of Mad2 to Xenopus egg extracts results in inhibition of cyclin B degradation and mitotic arrest due to the inhibition of the ubiquitin ligase activity of the APC (Li et al., 1997). The overexpression of Mad2 from fission yeast causes mitotic arrest by activating the spindle checkpoint (He et al., 1997). Whereas, introducing anti-Mad2 antibodies into mammalian cell cultures causes early transition to anaphase in the absence of microtubule drugs, indicating that Mad2 is involved in the normal cell cycle. Several reports suggest that different Mad2 homologs directly interact with the APC (Li et al., 1997; Fang et al., 1998; Kallio et al., 1998). Another protein called Cdc20 in S. cerevisiae binds to the APC, is required for activation of the APC during certain cell cycles, and Mad2 binds to it (Hwang et al., 1998; Kim et al., 1998; Lorca et al., 1998; Wassmann and Benezra, 1998). The picture that is emerging from all of these exciting findings is that Mad2 acts as an inhibitor of the APC, probably by binding to Cdc20. When Mad2 is not present, the Cdc20 binds to the APC, which activates the APC to degrade inhibitors of the transition to anaphase.
The plant spindle checkpoint: A possible target of bacterial pathogens. Many of the cell cycle proteins from animals have homologs in plants (Mironov et al., 1999). In fact, one of the early clues that there existed a spindle checkpoint was first made in plants. The observation noted was that chromosomes that lagged behind in their attachment to the spindle caused a delay in the transition to anaphase (Bajer and Mole-Bajer, 1956). Moreover, mad2 has been recently isolated from corn and the Mad2 protein localization in plant cells undergoing mitosis is consistent with the localization of Mad2 in other systems (Yu et al., 1999). Based on a published meeting report, genes that encode components of the APC from Arabidopsis have been recently cloned (Inze et al., 1999). Thus, it appears that a functional spindle checkpoint probably is conserved in plants. The data presented above shows that the P. syringae HopPsyA protein interacts with the Arabidopsis Mad2 protein in the yeast 2-hybrid system.
It is possible that a pathogenic strategy of a bacterial plant pathogen is to alter the plant cell cycle. Duan et al. recently reported that pthA, a member of the avrBs3 family of avr genes from X. citri, is expressed in citrus and causes cell enlargement and cell division, which may implicate the plant cell cycle (Duan et al., 1999). If HopPsyA does target Mad2, at least two possible benefits to pathogenicity can be envisioned. Since plant cells in mature leaves are quiescent, one benefit of delivering HopPsyA into these cells may be that it may trigger cell division through its interaction with Mad2. This is consistent with the observation that anti-Mad2 antibodies cause an early onset of anaphase in mammalian cells (Gorbsky et al., 1998). More plant cells near the pathogen may increase the nutrients available in the apoplast. A second possible benefit may occur if HopPsyA is delivered into plant cells actively dividing in young leaves. Delivery of HopPsyA into plant cells of these leaves may derail the spindle checkpoint through its interaction with Mad2. These cells would be prone to more mistakes segregating their chromosomes; in some cells this would result in death and the cellular contents would ultimately leak into the apoplast providing nutrients for the pathogen.
Cytotoxic Effects of HopPtoA and HopPsyA Expressed in Yeast
Both hopPtoA (SEQ. ID. No. 6) and hopPsyA (SEQ. ID. No. 35) were first cloned into pFLAG-CTC (Kodak) to generate an in-frame fusion with the FLAG epitope, which permitted monitoring of protein production with anti-FLAG monoclonal antibodies. The FLAG-tagged genes were then cloned under the control of the GAL1 promoter in the yeast shuttle vector p415GAL1 (Mumberg et al., 1994). These regulatable promoters of Saccharomyces cerevisiae allowed comparison of transcriptional activity and heterologous expression. The recombinant plasmids were transformed into uracil auxotrophic yeast strains FY833/4, selecting for growth on SC-Ura (synthetic complete medium lacking uracil) based on the presence of the URA3 gene on the plasmid. The transformants were then streaked onto SC-Ura medium plates containing either 2% galactose (which will induce expression of HopPsyA and HopPtoA) or 2% glucose. No growth was observed on the plates supplemented with 2% galactose. This effect was observed with repeated testing and was not observed with empty vector controls, with four other effectors similarly cloned into p415GAL1, or when raffinose was used instead of galactose. FLAG-tagged nontoxic Avr proteins were used to confirm that the genes were differentially expressed, as expected, on plates containing galactose. Importantly, the toxic effect with HopPsyA was observed when the encoding gene was recloned into p416GALS, which expresses foreign genes at a substantially lower level than p415GAL1.
Each of the references cited herein or otherwise listed below are expressly incorporated by reference in their entirety into this specification.
Although the invention has been described in detail for the purposes of illustration, it is understood that such detail is solely for that purpose, and variations can be made therein by those skilled in the art without departing from the spirit and scope of the invention which is defined by the following claims.
This application is a divisional of U.S. patent application Ser. No. 09/825,414, filed Apr. 3, 2001, now U.S. Pat. No. 6,852,835, issued Feb. 8, 2005, which claims benefit of U.S. Provisional Patent Application Ser. No. 60/194,160, filed Apr. 3, 2000, Ser. No. 60/224,604, filed Aug. 11, 2000, and Ser. No. 60/249,548, filed Nov. 17, 2000, which are hereby incorporated by reference in their entirety.
This work was supported by National Science Foundation Grant No. MCB-9631530 and National Research Initiative Competitive Grants Program, U.S. Department of Agriculture, Grant No. 98-35303-4488. The U.S. Government may have certain rights in this invention.
| Number | Name | Date | Kind |
|---|---|---|---|
| 5939601 | Klessig et al. | Aug 1999 | A |
| 6066451 | Avraham et al. | May 2000 | A |
| 6342654 | Li et al. | Jan 2002 | B1 |
| Number | Date | Country |
|---|---|---|
| WO 9832844 | Jul 1998 | WO |
| WO 0119393 | Mar 2001 | WO |
| Number | Date | Country | |
|---|---|---|---|
| 20050039232 A1 | Feb 2005 | US |
| Number | Date | Country | |
|---|---|---|---|
| 60249548 | Nov 2000 | US | |
| 60224604 | Aug 2000 | US | |
| 60194160 | Apr 2000 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 09825414 | Apr 2001 | US |
| Child | 10893776 | US |
